Next Article in Journal
Understanding the Interaction Determinants of CAPN1 Inhibition by CAST4 from Bovines Using Molecular Modeling Techniques
Next Article in Special Issue
Cyclin-Dependent Kinase Inhibitors as Marketed Anticancer Drugs: Where Are We Now? A Short Survey
Previous Article in Journal
On the Nature of the Transition State Characterizing Gated Molecular Encapsulations
Previous Article in Special Issue
Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance
Article Menu

Export Article

Open AccessReview
Molecules 2014, 19(9), 14304-14315; doi:10.3390/molecules190914304

Inhibition of the PI3K/Akt/mTOR Signaling Pathway in Diffuse Large B-Cell Lymphoma: Current Knowledge and Clinical Significance

Department of Experimental Hematology, Medical University of Lodz, 93-510 Lodz, Poland
*
Author to whom correspondence should be addressed.
Received: 22 July 2014 / Revised: 3 September 2014 / Accepted: 9 September 2014 / Published: 11 September 2014
(This article belongs to the Special Issue Design and Study of Kinase Inhibitors)
View Full-Text   |   Download PDF [1133 KB, uploaded 15 September 2014]   |  

Abstract

Diffuse large B-cell lymphoma (DLBCL) is one of the most common non-Hodgkin lymphomas in adults. The disease is very heterogeneous in its presentation, that is DLBCL patients may differ from each other not only in regard to histology of tissue infiltration, clinical course or response to treatment, but also in respect to diversity in gene expression profiling. A growing body of knowledge on the biology of DLBCL, including abnormalities in intracellular signaling, has allowed the development of new treatment strategies, specifically directed against lymphoma cells. The phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling pathway plays an important role in controlling proliferation and survival of tumor cells in various types of malignancies, including DLBCL, and therefore it may be a promising target for therapeutic intervention. Currently, novel anticancer drugs are undergoing assessment in different phases of clinical trials in aggressive lymphomas, with promising outcomes. In this review we present a state of art review on various classes of small molecule inhibitors selectively involving PI3K/Akt/mTOR pathway and their clinical potential in this disease. View Full-Text
Keywords: diffuse large B-cell lymphoma; PI3K kinase; Akt kinase; mTOR kinase; inhibitor; treatment diffuse large B-cell lymphoma; PI3K kinase; Akt kinase; mTOR kinase; inhibitor; treatment
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Majchrzak, A.; Witkowska, M.; Smolewski, P. Inhibition of the PI3K/Akt/mTOR Signaling Pathway in Diffuse Large B-Cell Lymphoma: Current Knowledge and Clinical Significance. Molecules 2014, 19, 14304-14315.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top